Connection

Perry Halushka to Platelet Aggregation Inhibitors

This is a "connection" page, showing publications Perry Halushka has written about Platelet Aggregation Inhibitors.
  1. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003 Jan; 73(1):122-30.
    View in: PubMed
    Score: 0.175
  2. Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. Cardiovasc Surg. 1997 Feb; 5(1):92-8.
    View in: PubMed
    Score: 0.116
  3. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. J Pharmacol Exp Ther. 1994 Sep; 270(3):1192-6.
    View in: PubMed
    Score: 0.024
  4. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug; 262(2):632-7.
    View in: PubMed
    Score: 0.021
  5. Difluorothromboxane A2 and stereoisomers: stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels. Proc Natl Acad Sci U S A. 1989 Jul; 86(14):5600-4.
    View in: PubMed
    Score: 0.017
  6. Do platelets have anything to do with diabetic microvascular disease? Diabetes. 1983 May; 32 Suppl 2:14-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.